Guardant Health, a three-year-old start-up has raised nearly $100 million in Series D funding. The financing was led by OrbiMed Advisors. The California based company developed a non-invasive genomic sequencing test for cancer which requires just two vials of blood.  Guardant has now raised almost $200 million altogether. Read More>>